14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
IIF vs RDY: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Dr. Reddy's Laboratories Limited (RDY) is the stronger overall head-to-head candidate over Morgan Stanley India Investment Fund, Inc. (IIF) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IIF carries a Unified Composite Score of 31.5/100 (SELL) at $23.43 (N/M Forward P/E, N/A operating margin), whereas RDY carries 34.7/100 (SELL) at $14.70 (31.6x Forward P/E, 9.1% operating margin).
Defensive Composite Rating Caution: Although RDY compares more favorably head-to-head, both IIF (31.5/100 SELL) and RDY (34.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IIF vs RDY. Trailing 12-month operating profitability (IIF N/A vs RDY 9.1%) and valuation multiples (IIF N/M vs RDY 31.6x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $12.3B market capitalization and 9.1% operating margin.
OpEx & R&D Reinvestment40.4% of Rev ($1.43B)
90D Engineering Disclosures0 Published
Investor FAQ IIF vs RDY Key Questions & Quantitative Answers
As of Nov 16, 2026, Dr. Reddy's Laboratories Limited (RDY) is the stronger overall head-to-head candidate over Morgan Stanley India Investment Fund, Inc. (IIF) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IIF carries a Unified Composite Score of 31.5/100 (SELL) at $23.43 (N/M Forward P/E, N/A operating margin), whereas RDY carries 34.7/100 (SELL) at $14.70 (31.6x Forward P/E, 9.1% operating margin). Defensive Composite Rating Caution: Although RDY compares more favorably head-to-head, both IIF (31.5/100 SELL) and RDY (34.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
RDY leads the Growth & Scale pillar: IIF posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with RDY at -1.5% YoY revenue growth and -35.7% YoY earnings growth on $3.53B TTM revenue (49.5% gross margin, 9.1% operating margin). On trailing 12-month operating scale, IIF generates N/A in USD-normalized revenue versus $3.53B for RDY. In operating R&D and SG&A reinvestment, IIF deploys N/A (0 90-day corporate R&D disclosures) versus 40.4% of Rev ($1.43B) (0 disclosures) for RDY.
RDY screens cheaper on headline valuation multiples. IIF trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas RDY trades at 31.6x Forward P/E, 40.9x Trailing P/E, 2.01x PEG, and 3.5x EV/Revenue (15.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IIF (N/A ROE) versus RDY (7.3% ROE) capital efficiency.
In options market volatility and institutional positioning, IIF carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.69β · 21% Vol realized risk). By comparison, RDY carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.39β · 24% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.